• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    10/30/23 4:22:02 PM ET
    $OTEC
    Blank Checks
    Finance
    Get the next $OTEC alert in real time by email
    425 1 g083826_8k.htm 8-K

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 27, 2023

     

    OceanTech Acquisitions I Corp.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-40450   85-2122558
    (Commission File Number)   (IRS Employer Identification No.)

     

    515 Madison Avenue, Suite 8133

    New York, New York 10022

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code (929) 412-1272

     

    _________________________________

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
      ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
         

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange on
    Which Registered
    Units, each consisting of one share of Class A Common Stock and one Redeemable Warrant   OTECU   The Nasdaq Stock Market LLC
    Class A Common Stock, $0.0001 par value per share   OTEC   The Nasdaq Stock Market LLC
    Redeemable Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share   OTECW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

      

     

     

      Item 8.01. Other Events.

     

    On October 30, 2023, OceanTech Acquisitions I Corp., a Delaware corporation (the “Company”), issued a press release announcing that it caused to be deposited $30,000 into the Company’s trust account on October 27, 2023, for its public stockholders, allowing the Company to extend the period of time it has to consummate its initial business combination by one month from November 2, 2023 to December 2, 2023 (the “Extension”). The Extension is the sixth of twelve, 1-month extensions permitted under the Company’s governing documents.

     

    A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

      Item 9.01. Financial Statements and Exhibits.

     

    (d)       Exhibits.

     

    Exhibit No.   Description
         
    99.1   Press Release dated October 30, 2023
         
    104   Cover Page Interactive Data File (Embedded within the Inline XBRL document)

      

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    OCEANTECH ACQUISITIONS I CORP.

     

     

         
    Date: October 30, 2023 By: /s/ Suren Ajjarapu
        Name: Suren Ajjarapu
        Title: Chief Executive Officer
        (Principal Executive Officer)

     

      

     

     

     

     

    Get the next $OTEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTEC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OceanTech Acquisitions I Corp. Announces Redemption of Shares

    OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on May 30, 2023, at the special meeting of the stockholders of the Company, holders of 1,035,788 shares of Class A common stock of the Company (the "Redeeming Stockholders") exercised the right to redeem such shares. On June 2, 2023, the Company made cash payments to the Redeeming Stockholders totaling $11,233,820 representing approximately $10.84 per share. Following such payments to the Redeeming Stockholders, the Company's trust account had a balance of approximately $8,814,443. About OceanTech Acquisitions I Corp. OceanTech is a blank check company

    6/7/23 9:29:00 AM ET
    $OTEC
    Blank Checks
    Finance

    OceanTech Acquisitions I Corp. Announces Postponement of Special Meeting of Stockholders Until May 30, 2023 at 11:30 a.m. EDT

    OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, previously filed a definitive proxy statement / final prospectus with respect to a special meeting of its stockholders to be held on Friday, May 26, 2023 at 1:00 p.m. EDT (the "Special Meeting") to vote on, among other things, a proposal to approve an amendment to OceanTech's amended and restated certificate of incorporation to extend the date by which OceanTech must consummate its initial business combination from June 2, 2023 by up to twelve (12) one-month extensions through June 2, 2024, or such earlier date as determined by OceanTech's board of directors. The Company is

    5/25/23 11:09:00 PM ET
    $OTEC
    Blank Checks
    Finance

    Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.

    Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac

    5/3/23 7:45:00 AM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    SEC Filings

    View All

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/13/24 4:52:09 PM ET
    $OTEC
    Blank Checks
    Finance

    OceanTech Acquisitions I Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - OceanTech Acquisitions I Corp. (0001846809) (Filer)

    2/13/24 4:50:55 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    1/30/24 4:06:26 PM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Owl Creek Asset Management, L.P.

    4 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    6/1/23 9:18:13 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Aspire Acquistion Llc

    3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    4/25/23 1:02:27 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Fell Donald G.

    3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    4/21/23 6:27:45 PM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Financials

    Live finance-specific insights

    View All

    Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.

    Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac

    5/3/23 7:45:00 AM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/13/24 5:54:33 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/5/24 2:07:43 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    1/10/24 11:01:25 AM ET
    $OTEC
    Blank Checks
    Finance